Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for serious and rare diseases, today announced that the Compensation Committee of the company's Board of Directors, made up entirely of independent directors, approved the grant of non-qualified stock options to purchase an aggregate of 171,900 shares of the company's common stock to 3 new employees (the.

Business Wire • Dec 5, 2025

Viridian Therapeutics Is Ready For An Eventful 2026

A slow period for Viridian Therapeutics, Inc. is coming to its conclusion. VRDN has recently completed financing transactions that put it on track to achieve profitability without additional dilution. Roche's Enspryng (satralizumab) has generated disappointing phase 3 results in thyroid eye disease patients, easing concerns about competition to veligrotug and VRDN-003 from the IL-6 antibody class.

Seeking Alpha • Nov 6, 2025

Viridian Therapeutics Reports Third Quarter 2025 Financial Results and Highlights Recent Progress

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for serious and rare diseases, today reported recent business highlights and financial results for the third quarter ended September 30, 2025. “The Viridian team continues to deliver strong results, highlighted by the successful submission of our BLA for veligrotug, completing enrollment in both pivotal c.

Business Wire • Nov 5, 2025

Viridian Therapeutics, Inc. (VRDN) Reports Q3 Loss, Tops Revenue Estimates

Viridian Therapeutics, Inc. (VRDN) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.82. This compares to a loss of $1.15 per share a year ago.

Zacks Investment Research • Nov 5, 2025

Viridian Therapeutics, Inc. (VRDN) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

Viridian Therapeutics (VRDN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research • Nov 4, 2025

Viridian Therapeutics Announces Successful October Submission of Biologics License Application (BLA) to U.S. FDA for Veligrotug in Thyroid Eye Disease

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for serious and rare diseases, today announced the successful October submission of its BLA to the U.S. Food and Drug Administration (FDA) for veligrotug, the company's investigational therapy for the treatment of thyroid eye disease (TED). TED is a rare, debilitating autoimmune disorder characterized by.

Business Wire • Nov 3, 2025

Insiders Are Buying These 3 Stocks Hand Over Fist

Insider buys can be a telltale sign of a turnaround, as these investments give you a window into where management stands with a company.

24/7 Wall Street • Oct 28, 2025

Viridian Therapeutics Announces Proposed Underwritten Public Offering

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering, developing and commercializing potential best-in-class medicines for serious and rare diseases, today announced that it has commenced an underwritten public offering of shares of its common stock and Series B non-voting convertible preferred stock. All of the securities to be sold in the underwritten public offering are being offered by Viridian. In addition, Viridian int.

Business Wire • Oct 21, 2025

Viridian Therapeutics Announces Pricing of $251 Million Public Offering of Shares of Common Stock

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering, developing and commercializing potential best-in-class medicines for serious and rare diseases, today announced the pricing of an underwritten public offering of shares of its common stock. Viridian is selling a total of 11,425,000 shares of common stock at a public offering price of $22.00 per share. In addition, Viridian has granted the underwriters a 30-day option to p.

Business Wire • Oct 22, 2025

Viridian Therapeutics Announces Royalty Financing with DRI Healthcare for up to $300 Million

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering, developing and commercializing potentially best-in-class medicines for serious and rare diseases, today announced it entered into a royalty financing agreement with DRI Healthcare Acquisitions LP (DRI) and accelerated its timelines for the submission of the veligrotug BLA and the topline clinical data readouts of its VRDN-003 REVEAL trials in patients with thyroid eye dis.

Business Wire • Oct 20, 2025